Related Experiment Videos
Multiple drug resistance parameter expression in ovarian cancer
F Joncourt1, K Buser, H Altermatt
1Institute for Clinical and Experimental Cancer Research, Tiefenaustrasse 120, Bern, Switerland.
Gynecologic Oncology
|September 19, 1998
Summary
Drug resistance in ovarian cancer is complex. Elevated detoxifying system components (DRPs) in tumors vary per patient and don't predict treatment response, hindering therapy recommendations.
Area of Science:
- Oncology
- Biochemistry
- Cancer Research
Background:
- Drug resistance is a major challenge in ovarian cancer treatment.
- Understanding resistance mechanisms is crucial for improving patient outcomes.
Purpose of the Study:
- To assess multiple drug resistance parameters (DRPs) in ovarian cancer tissue.
- To correlate these DRPs with clinical factors and prognosis.
Main Methods:
- Biochemical and Western blot analyses were performed on tumor and adjacent non-tumor ovarian tissues from 39 patients.
- Assessed parameters included glutathione (GSH), glutathione S-transferase (GST), glutathione-peroxidase (GPx), O6-alkylguanine-DNA alkyltransferase (Atase), topoisomerase II (TOPO), and P-glycoprotein (Pgp).
Main Results:
- Significant interindividual variations in DRP expression were observed.
- Elevated GSH, GST, GPx, and Atase levels/activities were found in tumor tissues compared to non-tumor tissues (P < 0.05).
- GSH levels increased with tumor stage (P < 0.002), with similar trends for GST, GPx, and Atase. No significant correlation was found between DRPs and other prognostic factors or treatment response.
Conclusions:
- Elevated DRPs indicate an intrinsic detoxification system pattern within ovarian tumors.
- Patient-specific DRP profiles may explain the difficulty in assessing their clinical significance for targeted therapies.